Author

Albert Hung

Columbia University Irving Medical CenterORCID 0000-0003-1213-4543Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

David A. BakeriD· 2 shared Domenico AcciliiD· 2 shared Eunhee ChoiiD· 2 shared Michelle Ng· 2 shared Sarah Caixeta Cardoso· 2 shared Xinru WangiD· 2 shared Brian CoventryiD· 1 shared Catherine HalliD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

David A. BakerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintMay 7, 2026

Reprogramming insulin receptor activation with a de novo agonist to overcome severe insulin resistance

Albert Hung, Xinru Wang, Michael Gao…·Eunhee Choi

This study develops a de novo insulin receptor agonist, RF-409, which effectively treats severe insulin resistance in a mouse model by activating a mutant receptor and improving glucose homeostasis.

DOI 10.64898/2026.05.04.722722

mouseproteomics

𝕏 PostBluesky

BioengineeringMolecular CellPeer-reviewedOct 15, 2025

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists

Xinru Wang, Sarah Caixeta Cardoso, Kai Cai…·David A. Baker

This paper designs synthetic insulin receptor agonists that modulate receptor conformation and signaling, showing improved potency and activity in disease mutants.

25 citationstop 2%

humanproteomics

𝕏 PostBluesky